ENXTBR:UCB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally.

Rewards

Earnings are forecast to grow 7.12% per year

Earnings grew by 13.8% over the past year

Risk Analysis

No risks detected for UCB from our risk checks.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has UCB's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UCB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.9%

UCB

-2.6%

BE Pharmaceuticals

0.03%

BE Market


1 Year Return

47.9%

UCB

6.6%

BE Pharmaceuticals

-22.8%

BE Market

Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned 7% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned -23.8% over the past year.


Shareholder returns

UCBIndustryMarket
7 Day-4.9%-2.6%0.03%
30 Day-4.0%-4.3%-2.8%
90 Day19.7%-6.0%6.9%
1 Year49.4%47.9%9.8%6.6%-21.6%-22.8%
3 Year85.6%79.0%27.7%13.0%-25.8%-30.3%
5 Year53.8%44.9%20.3%-0.3%-20.9%-29.5%

Price Volatility Vs. Market

How volatile is UCB's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is UCB undervalued compared to its fair value and its price relative to the market?

26.05x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: UCB (€102.85) is trading above our estimate of fair value (€70.29)

Significantly Below Fair Value: UCB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: UCB is poor value based on its PE Ratio (26x) compared to the XE Pharmaceuticals industry average (22.1x).

PE vs Market: UCB is poor value based on its PE Ratio (26x) compared to the Belgian market (13.6x).


Price to Earnings Growth Ratio

PEG Ratio: UCB is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: UCB is good value based on its PB Ratio (2.7x) compared to the XE Pharmaceuticals industry average (3.5x).


Next Steps

Future Growth

How is UCB forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

7.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UCB's forecast earnings growth (7.1% per year) is above the savings rate (1.6%).

Earnings vs Market: UCB's earnings (7.1% per year) are forecast to grow slower than the Belgian market (25.6% per year).

High Growth Earnings: UCB's earnings are forecast to grow, but not significantly.

Revenue vs Market: UCB's revenue (1.4% per year) is forecast to grow slower than the Belgian market (5.2% per year).

High Growth Revenue: UCB's revenue (1.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UCB's Return on Equity is forecast to be low in 3 years time (11.2%).


Next Steps

Past Performance

How has UCB performed over the past 5 years?

19.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UCB has high quality earnings.

Growing Profit Margin: UCB's current net profit margins (14.3%) are higher than last year (13.9%).


Past Earnings Growth Analysis

Earnings Trend: UCB's earnings have grown by 19.4% per year over the past 5 years.

Accelerating Growth: UCB's earnings growth over the past year (13.8%) is below its 5-year average (19.4% per year).

Earnings vs Industry: UCB earnings growth over the past year (13.8%) exceeded the Pharmaceuticals industry 11.2%.


Return on Equity

High ROE: UCB's Return on Equity (10.8%) is considered low.


Next Steps

Financial Health

How is UCB's financial position?


Financial Position Analysis

Short Term Liabilities: UCB's short term assets (€3.1B) exceed its short term liabilities (€2.6B).

Long Term Liabilities: UCB's short term assets (€3.1B) do not cover its long term liabilities (€3.6B).


Debt to Equity History and Analysis

Debt Level: UCB's debt to equity ratio (39.1%) is considered satisfactory.

Reducing Debt: UCB's debt to equity ratio has reduced from 45.2% to 39.1% over the past 5 years.

Debt Coverage: UCB's debt is well covered by operating cash flow (32.7%).

Interest Coverage: UCB's interest payments on its debt are well covered by EBIT (22.4x coverage).


Balance Sheet


Next Steps

Dividend

What is UCB current dividend yield, its reliability and sustainability?

1.21%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: UCB's dividend (1.21%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (2.56%).

High Dividend: UCB's dividend (1.21%) is low compared to the top 25% of dividend payers in the Belgian market (5.49%).


Stability and Growth of Payments

Stable Dividend: UCB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are stable.

Growing Dividend: UCB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: UCB is not paying a notable dividend for the Belgian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UCB's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jean-Christophe Tellier (61 yo)

5.58yrs

Tenure

€87,000

Compensation

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since ...


CEO Compensation Analysis

Compensation vs Market: Jean-Christophe's total compensation ($USD102.34K) is below average for companies of similar size in the Belgian market ($USD2.52M).

Compensation vs Earnings: Jean-Christophe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jean-Christophe Tellier
CEO & Executive Director5.58yrs€87.00kno data
Dhavalkumar Patel
Executive VP & Chief Scientific Officer2.83yrsno datano data
William Silbey
Executive VP & General Counsel1.42yrsno datano data
Jean-Luc Fleurial
Executive VP & Chief Human Resources Officer0.50yrno datano data
Iris Löw-Friedrich
Chief Medical Officer12.42yrsno datano data
Emmanuel Caeymaex
Executive VP of Immunology Solutions & Head of US5.5yrsno datano data
Charl Van Zyl
Executive VP of Neurology Solutions & Head of EU/International0.92yrno datano data
Sandrine Dufour
Executive VP & CFO0.083yrno datano data
Caroline Vancoillie
Chief Accounting Officer & CFO of Patient Value Functions7.42yrsno datano data
Kirsten Lund-Jurgensen
Executive Vice President of Supply & Technology Solutions0.92yrno datano data
Antje Witte
Head of Investor Relations10.58yrsno datano data
Gwendoline Ornigg
Head of Global Communicationno datano datano data

2.8yrs

Average Tenure

59yo

Average Age

Experienced Management: UCB's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jean-Christophe Tellier
CEO & Executive Director5.58yrs€87.00kno data
Gerhard Mayr
Honorary Chairmanno data€70.00kno data
Mark Eyskens
Honorary Chairman15.58yrs€15.50kno data
Daniel Janssen
Honorary Deputy Chairmanno data€28.50kno data
Frederic Doliveux
Director3.25yrs€87.00kno data
Albrecht De Graeve
Independent Director10.33yrs€120.50kno data
Georges Jacobs Hagen
Honorary Chairmanno data€30.00kno data
Diégo du de Bergendal
Chairman3.25yrs€262.50kno data
Karel Boone
Honorary Chairmanno data€49.00kno data
Charles-Antoine Emmanuel Janssen
Director8.33yrs€108.50kno data
Kay Davies
Independent Director6.33yrs€137.50kno data
Pierre Gurdjian
Independent Vice Chairman3.25yrs€147.50kno data

6.3yrs

Average Tenure

69yo

Average Age

Experienced Board: UCB's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

UCB SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UCB SA
  • Ticker: UCB
  • Exchange: ENXTBR
  • Founded: 1928
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €19.451b
  • Shares outstanding: 189.12m
  • Website: https://www.ucb.com

Number of Employees


Location

  • UCB SA
  • AllEe de la Recherche, 60
  • Brussels
  • Brussels
  • 1070
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UCBJ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1980
UNCDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1980
UCBENXTBR (Euronext Brussels)YesCommon SharesBEEURJan 1980
0NZTLSE (London Stock Exchange)YesCommon SharesGBEURJan 1980
UCBBBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJan 1980
UCBWBAG (Wiener Boerse AG)YesCommon SharesATEURJan 1980
UNCETLX (Eurotlx)YesCommon SharesITEURJan 1980
UCBJ.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDFeb 2009

Biography

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company’s primary products inc ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/10 20:56
End of Day Share Price2020/08/10 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.